Search PubMed⌕ Search

Biomedical subjects

W Guy

Publications and source records attributed to W Guy.

At least 37 records · Page 2Linked to original sources
PubMed1982

A collaborative study of a new antidepressant, viloxazine, in neurotic and endogenous depressives.

In a multicenter series of trials, viloxazine was compared with imipramine, amitriptyline, doxepin and placebo in 123 neurotic and endogenous depressive inpatients and outpatients. While significant period effects reflecting improvement were obtained on the majority of efficacy variables, no significant differences were obtained among the treatment groups or depressive types. Imipramine and amitriptyline exhibited more anticholinergic adverse reactions; while, viloxazine exhibited greater CNS effects. Dizziness and nausea were much more frequent in neurotic depressives which may be related to their psychopathology.

Adolescent↗
PubMed1982

Psychopharmacology and Leonhard's classification of chronic schizophrenias.

There is evidence to indicate that 15% of patients diagnosed as schizophrenic will become chronically hospitalized, and that worldwide one-third to one-half of all psychiatric beds are occupied by schizophrenic patients. In spite of these figures and the public health problem they represent, little attention is paid to chronic hospitalized schizophrenic patients. Even the most recent classification schemas fail to recognize the heterogeneity, exemplified by differential responsiveness to psychotropic drugs, within the chronic schizophrenic population. One systematic approach to classification which does address this problem has been proposed by Leonhard. In this paper, findings and procedures that demonstrate the clinical relevance of Leonhard's system along with some preliminary results and observations from psychopharmacological studies that indicate Leonhard's different subtypes of chronic schizophrenia may represent biologically distinct populations are presented.

Antipsychotic Agents↗
PubMed1982

Viloxazine in the treatment of endogenous depression. A standard (amitriptyline) controlled clinical study.

In a double-blind clinical trial with 20 patients suffering from endogenous depression statistically significant changes (improvement) were present in the scores of all assessment instruments. Although no statistically significant differences occurred between the groups, significant improvement on the HAM-D occurred earlier for amitriptyline and significant improvement occurred earlier on HAM-A for viloxazine. 2 patients were discontinued due to adverse reactions; one for nausea and vomiting while receiving viloxazine and one for paroxysmal atrial tachycardia while receiving amitriptyline. The same number of TES occurred for each group with seven unique to viloxazine (numbness, tingling, palpitation, ejaculation difficulty, nausea/vomiting, diarrhea, epigastric pain and gustatory disturbances) and seven unique to amitriptyline (insomnia, irritability, syncope, tremor, nasal congestion, orthostatic hypertension and paroxysmal atrial tachycardia). Other than for 1 patient who developed syncope and orthostatic hypotension and the patient who developed paroxysmal atrial tachycardia, there were no clinically significant changes in pulse rate, blood pressure and weight. There were no clinical laboratory findings with either drug that were judged to be pathological.

Adolescent↗
PubMed1982

Viloxazine HCl in the treatment of endogenous depression: a standard (imipramine) controlled clinical study.

In a four week, double-blind clinical trial, 20 patients with endogenous depression were randomly assigned to treatment with either viloxazine or imipramine. Statistically significant improvement was observed on the Hamilton Psychiatric Rating Scales for Depression and Anxiety for both treatment groups. There were no differences between the two treatment groups in the type, incidence, or severity of treatment emergent symptoms. No medication-related abnormalities in clinical laboratory values occurred in either treatment group.

Adult↗
PubMed1981

Measuring chronic schizophrenic patients attitudes toward their illness and treatment.

The right to refuse medication is a legal right now being extended by federal courts to many voluntary and involuntary mental patients. However, little is known of the insight that chronically ill mental patients bring to the decision of whether or not to accept prescribed medication. In this study, the authors interviewed 45 chronic schizophrenic inpatients to determine their understanding of their illness, need for admission, and need for medication and other treatment. Only 13 per cent understood they were mentally ill, and only 27 per cent of the patients understood that they needed medication. The findings suggest that many chronically mentally ill patients lack sufficient insight into their condition to make sound judgments about medication and treatment. Moreover, even those patients who improved with medication did not improve in their insight into their need for treatment.

Adolescent↗
PubMed1980

Mianserin: determination of therapeutic dose range.

Mianserin hydrochloride is a tetracyclic antidepressant with an EEG and clinical activity profile similar to amitriptyline. To investigate the drug's optimal dosage range, a 6-week open comparative trial sequentially assigned 12 depressed patients to one of three dose ranges (60, 90 and 120 mg). Improvement occurred in depressive symptomatology in all three treatment groups. There was no differential improvement noted in any group; however, the incidence of adverse effects was greater in the middle (90 mg) and high (120 mg) dose ranges.

Adult↗
PubMed1980

Viloxazine in the treatment of depressive neurosis: a placebo and standard (imipramine) controlled clinical study.

In a 4-week double-blind trial, 33 patients with depressive neurosis were randomly assigned to either viloxazine, imipramine or placebo. Statistically significant improvement was observed in all treatment groups. Imipramine exhibited significant improvement earlier in depressive symptoms, while viloxazine showed significant improvement earlier in anxious symptoms. The same frequency of treatment emergent symptoms occurred in the treatment groups. Premature termination as a consequence of adverse reactions was required in only 1 viloxazine and 1 placebo patient.

Adult↗
PubMed1980

A double-blind comparison of three dosages of flutroline (CP-36,584) in the treatment of schizophrenia.

Therapeutic and adverse effects of three dosages (1, 20 and 100 mg daily) of flutroline, a new gamma-carboline with a preclinical pharmacological profile similar to active neuroleptic agents, were compared in a double-blind clinical trial in 25 newly-admitted schizophrenic patients. Therapeutic effects and extrapyramidal signs were seen at the 20 and 100-mg daily dosages, but not at the 1-mg dosage. Serum prolactin levels were significantly elevated only at the 100-mg daily dosage.

Adolescent↗
PubMed1980

Viloxazine in the treatment of depressive neurosis: a controlled clinical study with doxepin and placebo.

In a four-week, double-blind, clinical trial thirty-one patients with depressive neurosis were treated with viloxazine, doxepin, or placebo. There were no differences among the three groups in therapeutic effects. Many depressed out-patients improve on placebo. Viloxazine hydrochloride is one of a series of compounds developed to explore the central nervous system activity of the aryloxypropanolamine type of beta-adreno-receptor antagonists. Initial clinical study support the hypothesis that viloxazine has antidepressant properties in man (Bayliss et al, 1974; Bereen, 1973; Pichot et al., 1975; Tsegos and Ekdawi, 1974).

Adult↗